XOMA Royalty (NASDAQ:XOMA) and Enzon Pharmaceuticals (OTCMKTS:ENZN) Head to Head Contrast

XOMA Royalty (NASDAQ:XOMA) and Enzon Pharmaceuticals (OTCMKTS:ENZN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Valuation & Earnings

This table compares XOMA Royalty and Enzon Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XOMA Royalty	$52.15 million	6.80	$31.71 million	$1.46	20.39
Enzon Pharmaceuticals	$30,000.00	148.42	-$3.41 million	($0.07)	-0.86

XOMA Royalty has higher revenue and earnings than Enzon Pharmaceuticals. Enzon Pharmaceuticals is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

95.9% of XOMA Royalty shares are owned by institutional investors. 7.2% of XOMA Royalty shares are owned by company insiders. Comparatively, 0.4% of Enzon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares XOMA Royalty and Enzon Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XOMA Royalty	45.75%	10.32%	3.49%
Enzon Pharmaceuticals	N/A	-263.18%	-10.11%

Analyst Recommendations

This is a summary of current recommendations and price targets for XOMA Royalty and Enzon Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XOMA Royalty	1	2	3	0	2.33
Enzon Pharmaceuticals	0	0	0	0	0.00

XOMA Royalty presently has a consensus price target of $61.60, suggesting a potential upside of 106.92%. Given XOMA Royalty’s stronger consensus rating and higher possible upside, analysts clearly believe XOMA Royalty is more favorable than Enzon Pharmaceuticals.

Risk and Volatility

XOMA Royalty has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Enzon Pharmaceuticals has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500.

Summary

XOMA Royalty beats Enzon Pharmaceuticals on 13 of the 14 factors compared between the two stocks.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.